Trial Profile
An open-label, multiple ascending dose study to determine the maximum tolerated dose of R1530 in patients with advanced solid tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 May 2013
Price :
$35
*
At a glance
- Drugs R-1530 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 12 May 2009 Actual end date (1 Feb 2009) added as reported by ClinicalTrials.gov.
- 18 Apr 2009 New source identified and integrated (Roche).
- 18 Apr 2009 New source identified and integrated (Roche).